| Popis: |
HCV is a lymphotropic virus that infects B-cells promoting favorable conditions for B lymphocyte proliferation. As a consequence, several lymphoproliferative disorders have been associated with the virus. Recently approved direct acting antiviral (DAAs) agents have revolutionized the treatment of chronic HCV infection, and will significantly improve the outcome of HCV associated B-NHL.our study aimed at evaluating the response of DAAs on HCV positive patients with NHL after complete chemotherapy of lymphoma. In this research, we evaluated 100 patients with chronic HCV infection with or without history of lymphoma after giving DAAs for 12 weeks. Both groups had 100% sustained virological response (SVR) at week 12 after treatment, while 96% of patients with history of lymphoma had SVR at week 24 in comparison to 100% SVR in the chronic HCV group, Moreover, 96% of patients had no relapsed lymphoma after treatment by DAAs. And hence, From the previous study we conclude that DAAs significantly improve the outcome of HCV associated B-NHL yet no significance difference was noted regarding SVR. Keywords: Hepatitis C virus, Directly acting antiviral drugs, Non-hodgkin lymphoma, sustained virological response. REFERENCES Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep2012;(61): 545. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, MizokamiM,et al.(1997). Hepatitis C virus infection in patients with B-cell non-hodgkinlymphoma.Ann Intern Med (6);127:423–428. Paydas S, Kilic B, Yavuz S, Disel U Tanriverdi K, SahinB,et al .(2003) Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-hodgkin’s lymphoma. Am J Hematol(5);74:89–93. Peveling-Oberhag J, ArcainiL,Hansmann ML, Zeuzem S.( 2013) . Hepatitis C associated B-cell non-hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol;59:169–177. Sulyok M, Makara M, Ujhelyi E, Valyi-Nagy I. (2015) Non-hodgkin lymphoma and hepatitis C: Where we are and what next? PatholOncol Res; 21:1–7. De Re V, Caggiari L , Simula MP , de Vita S , Sansonno D ,Dolcetti R. B-cell Lymphomas associated with HCV infection. Gastroenterology 2007; 132:1205-7. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM, et al. Interferon Alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 1992;( 327):1336–41. Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, et al (2014).Antiviraltreatment in patients with indolent Bcell lymphomas associated with HCV infection: A study of the fondazioneitalianalinfomi. Ann Oncol;25:1404–1410. Pawlotsky JM,( 2014). New hepatitis C virus (HCV) drugs and the hope for a cure:Concepts in anti-HCV drug development. Semin Liver Dis;34:22–29. Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F(2012). Indolent B-cell lymphomas associated with HCV infection: Clinical and virological features and role of antiviral therapy. Clin DevImmunol;20)12:638185. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and posttransplantation. J Hepatol 2014; (61):S120-31. Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006; 31: 1879–86. Alric L, PLaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J et al. Influence of antiviral therapy in hepatitis C virus associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617–23. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 789–94. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low grade, B-cell, non-hodgkin’s lymphoma: a multicenter Italian experience. J ClinOncol 2005; 23: 1468–73. Bonnet C, Lejeune M, Van Kemseke C, Bron D, Beguin Y(2015). Current management of marginal zone lymphomas. Rev Med Suisse; 11:1549-56. Tania Luthra, Rahul Agarwal, Mamidala Estari, Uma Adepally, Subhabrata Sen. A novel library of -arylketones as potential inhibitors of α-glucosidase: Their design, synthesis, in vitro and in vivo studies. Nature-Scientific Reports, 2017, 7(1), 1-13. DOI: 10.1038/s41598- 017-13798-y. Torres HA, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. Liver Int 2015; 35(6):1661–4. Mohamed S. Mohameda , Amr S. Hanafya , Mohamed A.A. Bassionya and Samia Husseinb, DAA in chronic hepatitis C patients. Eur J GastroenterolHepatol 2017. Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, etal.(2016) Prospective study of guideline tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology; 64:1473-82. Bonacci M, Lens S, Londoño MC, Mariño Z, Cid MC, Ramos-Casals M, et al. (2016).antiviral therapy. Rheumatology (Oxford); 55:2084–5. Sherigar JM, Gayam V, Khan A, Mukhtar O, Arefiev Y, Khalid M, et al. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J GastroenterolHepatol 2017; 29(7):767-76. Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 2015; (125): 2446-7. |
